Prostatype Genomics AB (PROGEN) Fair Value & Analysis
Healthcare · SE · Market cap 36.9M SEK
Fair value as of: Jul 16, 2026
From 1 valuation models · updated today
Fair value updated Jul 16, 2026 — revised from kr 2.02 to kr 0.1100 (−94.6%) since Jun 24, 2026. Share price −68.7% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 0.1256 – kr 1.95 · fair‑value band kr 0.0900 – kr 0.1700 · the kr 0.1785 price screens above the kr 0.1100 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Prostatype Genomics AB (PROGEN) currently trades at kr 0.1785, while our model-based Fair Value estimate is kr 0.1100 — implying the stock looks roughly 38.4% overvalued today. We read business quality at 16/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 594K SEK. Revenue declined 26.0% year over year. The balance sheet holds a net cash position of 3.8M SEK. Fundamentals as of Jul 16, 2026
Our scenario range runs from kr 0.0900 (bear case) to kr 0.1700 (bull case); at kr 0.1785, the current price sits above that range. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside — at -38%, PROGEN screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Solna, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Prostatype Genomics AB reported revenue of kr 594K in FY2025 versus kr 10.0K in FY2021, a compound +177.6%/yr. Reported net income was −kr 44.5M in FY2025.
Is PROGEN fairly valued? → Check now
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | 8,423 MXN | 314.17 MXN | -96% |
| Danaher Corporation DAP | €157.35 | €73.68 | -53% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| IDEXX Laboratories, Inc IDXX | $556.94 | $255.77 | -54% |
| Lonza Group LZAGY | $61.53 | $15.70 | -74% |
| Agilent Technologies, Inc A | $138.37 | $65.93 | -52% |
| Waters Corporation WAT | $371.93 | $87.58 | -76% |
| Integrated Diagnostics Holdings IDHC | $0.0056 | $0.0100 | +78% |
| IQVIA Holdings IQV | $167.81 | $133.89 | -20% |
| Natera, Inc NTRA | $216.50 | $39.79 | -82% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Prostatype Genomics AB (PROGEN) undervalued?
What is the fair value of PROGEN?
What is the quality score of PROGEN?
What is the revenue of Prostatype Genomics AB (PROGEN)?
What is the net profit margin of PROGEN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Tell me when Prostatype Genomics AB reaches its Fair Value
Just your email — and we'll notify you when the price and Fair Value of Prostatype Genomics AB materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.